Sophia Hober is Professor of Molecular Biotechnology at KTH, Stockholm, Sweden. Between 2003 and 2011 she was part of the executive management team of Human Proteome Atlas and from 2011 to 2015 part of the executive management team at KTH. She has published more than 100 scientific papers and supervised 17 PhD-students to their dissertation. The focus of her current research group is protein production, purification and characterization. Her group develops predictable and robust systems for protein purification and detection through protein design and various selection methodologies. Her key scientific achievements include design and development of gene fusion systems for selective ion-exchange purification and improvements of the alkaline tolerance of protein A for industrial purification of IgG (currently a product sold by GE Healthcare). Recently her group has developed a small bispecific protein domain to be used in cancer theranostics.
Professor Hober is principal investigator for the Cell Factories for the Human Secretome program. Moreover, Professor Hober heads a sub-project within the Next generation antibody therapeutics program .